Abstract
Introduction. Systemic thrombolysis with intravenous recombinant tissue plasminogen activator (rtPA) for acute ischemic stroke had been licensed for patients up to 75 years in age in many European countries and was recently extended to 80 years. This age restriction results from the potential higher risk of cerebral bleeding in the elderly. The major rtPA trials included only 42 patients above 80 years showing a potential benefit from treatment. Further data is still rare.
Methods. Using our stroke database we identified all patients beyond 75 years with middle cerebral artery ischemia treated with intravenous rtPA in our stroke unit from 02/1999 until 07/2004. Clinical course and outcome until day 5 in addition to mortality after 3 and 6 months were analysed.
Results. Twenty-nine patients (80.8 ± 4 years, 16 of them over 80 years old) met the inclusion criteria representing 21.2% of those receiving thrombolytic therapy. The median NIH-SS score on admission was 14 points. On day 5 after thrombolysis, 13/29 showed a good recovery (NIH-SS improvement ≥4 pts). The remaining exhibited only small or no benefit (n = 11), deterioration (n = 3) or died (n = 2). A total of 3/29 patients developed non-symptomatic parenchymal hemorrhage or hemorrhagic transformation. One patient died due to space-occupying cerebral hemorrhage. Extracerebral bleeding was found in 3/29 requiring substitution in one. One other died for primary cardiac reasons. Median NIH-SS on day 5 was 10 points. Mortality after 3 and 6 months was 20.7%. We did not find factors predicting clinical outcome. Most importantly, there was no significant difference regarding outcome in patients 76–80 vs. 81–87 years old.
Discussion. Intravenous rtPA resulted in good neurological in-hospital outcome in almost 45% and six-months survival of almost 80% of the patients beyond 75 years. In 10.3% non-symptomatic and in 3.4% symptomatic cerebral bleeding was found. Thus, seniors beyond 75 and even beyond 80 years in good medical condition may benefit from systemic treatment with rtPA. Prospective studies are needed to clarify which part of the senior population might be most eligible for systemic thrombolysis.
Similar content being viewed by others
References
Brown RD, Whisnant JP, Sicks JD, O’Fallon WM, Wiebers DO. Stroke incidence, prevalence, and survival: Secular trends in Rochester, Minnesota, through 1989. Stroke 1996;27(3):373–380.
Wittry MD, Thornton TA, Chaitman BR. Safe use of thrombolysis in the elderly. Geriatrics 1989;44(11):28–30,33–36.
Rich MW. Geriatric Cardiology. Cardiovasc Rev Rep 1991;12(3):11–13.
Gurwitz JH, Goldberg RJ, Gore JM. Coronary thrombolysis for the elderly? JAMA 1991;265(13):1720–1723.
Batty GM, Parry DS, Wilkins WE, Chappell AG. Thrombolysis for elderly patients with myocardial infarction: Experience in an integrated unit. Age Ageing 1994;23(3):220–222.
Devlin W, Cragg D, Jacks M, Friedman H, O’Neill W, Grines C. Comparison of outcome in patients with acute myocardial infarction aged > 75 years with that in younger patients. Am J Cardiol 1995;75(8):573–576.
Gurwitz JH, Gore JM, Goldberg RJ, Rubison M, Chandra N, Rogers WJ. Recent age-related trends in the use of thrombolytic therapy in patients who have had acute myocardial infarction. National Registry of Myocardial Infarction. Ann Intern Med 1996;124(3):283–291.
Angeja BG, Gibson CM, Chin R, Canto JG, Barron HV. Use of reperfusion therapies in elderly patients with acute myocardial infarction. Drugs Aging 2001;18(8):587–596.
Dennis MS, Burn JP, Sandercock PA, Bamford JM, Wade DT, Warlow CP. Long-term survival after first-ever stroke: The oxfordshire community stroke project. Stroke 1993;24(6):796–800.
Lai SM, Alter M, Friday G, Sobel E. Prognosis for survival after an initial stroke. Stroke 1995;26(11):2011–2015.
Sharma JC, Fletcher S, Vassallo M. Strokes in the elderly–-higher acute and 3-month mortality-an explanation. Cerebrovasc Dis 1999;9(1):2–9.
Olindo S, Cabre P, Deschamps R, Chatot-Henry C, Rene-Corail P, Fournerie P, Saint-Vil M, May F, Smadja D. Acute stroke in the very elderly: Epidemiological features, stroke subtypes, management, and outcome in Martinique, French West Indies. Stroke 2003;34(7):1593–1597.
The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue Plasminogen Activator for Acute Ischemic Stroke. N Engl J Med 1995;333:1581–1588.
Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998;352(9136):1245–1251.
Larrue V, von Kummer R, Muller A, Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: A secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke 2001;32(2):438–441.
Tanne D, Gorman MJ, Bates VE, Kasner SE, Scott P, Verro P, Binder JR, Dayno JM, Schultz LR, Levine SR. Intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 80 years and older: The tPA stroke survey experience. Stroke 2000;31(2):370–375.
Simon JE, Sandler DL, Warwick Pexman JH, Hill MD, Buchan AM for the Calgary Stroke Programme. Is intravenous recombinant tissue plasminogen activator (rt-PA) safe for use in patients over 80 years old with acute ischaemic stroke ?–The Calgary experience. Age and Ageing 2004;33:143–149.
Gorman MJ, Tanne D, Lewandowski CA. Centenarian stroke treated with tissue-type plasminogen activator. Cerebrovasc Dis 2002;13(4):285–287.
Wardlaw JM, Zoppo G, Yamaguchi T, Berge E. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev 2003;(3):CD000213.
Adams Jr HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24(1):35–41.
North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 1991;325(7):445–453.
Kolominsky-Rabas PL, Weber M, Gefeller O, Neundoerfer B, Heuschmann PU. Epidemiology of ischemic stroke subtypes according to TOAST criteria. Incidence, recurrence, and long-term survival in ischemic stroke subtypes: A population-based study. Stroke 2001;32(12):2735–2740.
Ford GA. Thrombolysis for stroke in the over 80s. Age and Ageing 2004;33:95–97.
Heuschmann PU, Kolominsky-Rabas PL, Roether J, Misselwitz B, Lowitzsch K, Heidrich J, Hermanek P, Leffmann C, Sitzer M, Biegler M, Buecker-Nott HJ, Berger K for the German Stroke Registers Study Group. Predictors of in-hospital mortality in patients with acute ischemic stroke treated with thrombolytic therapy. JAMA 2004 Oct 20;292(15):1831–1838.
Lindley RI, Wardlaw JM, Sandercock PA. Alteplase and ischaemic stroke: Have new reviews of old data helped? Lancet Neurol 2005;4(4):249–253.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Vatankhah, B., Dittmar, M.S., Fehm, N.P. et al. Thrombolysis for Stroke in the Elderly. J Thromb Thrombolysis 20, 5–10 (2005). https://doi.org/10.1007/s11239-005-2477-0
Issue Date:
DOI: https://doi.org/10.1007/s11239-005-2477-0